

**East Genomic Laboratory Hub**

<b>Solid Tumour Request Form</b>					
East GLH, Box 143, Level 6, Addenbrooke's Treatment Centre, Cambridge University Hospital NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ Phone: (01223) 586926 Email: <a href="mailto:add-tr.eastglhcancertests@nhs.net">add-tr.eastglhcancertests@nhs.net</a>					
Patient Details			Referral Information		
Surname			Consultant		
Forename			Hospital		
Date of Birth		M F	Ward/Clinic		
Hospital No.			Mobile/Bleep		
NHS No.			NHS.NET email for result return		
Specimen No:			Tissue Site:	Date specimen taken:	
<b>Specimen requirement: Representative formalin fixed paraffin embedded tissue sections</b> <ul style="list-style-type: none"> <li>• <b>FISH:</b> <i>2x2µm sections on charged slides for every probe requested + 1x H&amp;E stained slide.</i></li> <li>• <b>All other tests:</b> <i>10x5µm sections + 1x H&amp;E stained slide</i></li> </ul>					
Clinical details, diagnosis & reason for referral:					

 **B cell clonality analysis by PCR**  
*IGH/IGK/IGL rearrangement*
 **T cell clonality analysis by PCR**  
*TRG/TRB/TRD rearrangement*
**Chromosome analysis by interphase FISH**

<input type="checkbox"/> <i>IGH</i> gene involved translocations <input type="checkbox"/> Follicular lymphoma <input type="checkbox"/> MALT lymphoma <input type="checkbox"/> Mantle cell lymphoma <input type="checkbox"/> Burkitt lymphoma <input type="checkbox"/> High grade B cell lymphoma <input type="checkbox"/> Large B cell lymphoma with <i>IRF4</i> rearrangement <input type="checkbox"/> Anaplastic large cell lymphoma ALK-negative <input type="checkbox"/> Anaplastic large cell lymphoma <input type="checkbox"/> ALK-positive large B cell lymphoma	<input type="checkbox"/> <i>IGH</i> <input type="checkbox"/> <i>BCL2</i> <input type="checkbox"/> <i>IGH-BCL2</i> <input type="checkbox"/> <i>MALT1</i> <input type="checkbox"/> <i>BIRC3-MALT1</i> <input type="checkbox"/> <i>IGH-MALT1</i> <input type="checkbox"/> <i>CCND1</i> <input type="checkbox"/> <i>IGH-CCND1</i> <input type="checkbox"/> <i>MYC</i> <input type="checkbox"/> <i>IGH-MYC</i> <input type="checkbox"/> <i>MYC</i> <input type="checkbox"/> <i>IGH-MYC</i> <input type="checkbox"/> <i>BCL2</i> <input type="checkbox"/> <i>BCL6</i> <input type="checkbox"/> <i>IRF4/DUSP22</i> <input type="checkbox"/> <i>IRF4/DUSP22</i> <input type="checkbox"/> <i>ALK</i> <input type="checkbox"/> <i>ALK</i>
<input type="checkbox"/> Neuroblastoma <input type="checkbox"/> Ewings sarcoma etc. <input type="checkbox"/> Rhabdomyosarcoma <input type="checkbox"/> Dermatofibrosarcoma protuberans <input type="checkbox"/> Synovial sarcoma <input type="checkbox"/> Infantile fibrosarcoma <input type="checkbox"/> Liposarcoma <input type="checkbox"/> Alveolar soft part sarcoma <input type="checkbox"/> Inflammatory myofibroblastic tumour <input type="checkbox"/> Angiosarcoma	<input type="checkbox"/> <i>TOP2A</i> <input type="checkbox"/> 11q22.3(ATM) <input type="checkbox"/> <i>MYCN</i> <input type="checkbox"/> 1p36 <input type="checkbox"/> <i>EWSR1</i> <input type="checkbox"/> <i>FOXO1</i> <input type="checkbox"/> <i>PAX3</i> <input type="checkbox"/> <i>PAX7</i> <input type="checkbox"/> <i>PDGFB</i> <input type="checkbox"/> <i>SS18</i> <input type="checkbox"/> <i>ETV6</i> <input type="checkbox"/> <i>MDM2</i> <input type="checkbox"/> <i>TFE3</i> <input type="checkbox"/> <i>ALK</i> <input type="checkbox"/> <i>MYC</i>
<input type="checkbox"/> Oligodendroglioma <input type="checkbox"/> Medulloblastoma <input type="checkbox"/> Pilocytic astrocytoma	<input type="checkbox"/> 1p36 <input type="checkbox"/> 19q13 <input type="checkbox"/> <i>MYC</i> <input type="checkbox"/> <i>MYCN</i> <input type="checkbox"/> <i>KIAA1549-BRAF</i>
<input type="checkbox"/> Non-small cell lung cancer <input type="checkbox"/> Renal cell carcinoma <input type="checkbox"/> Mammary analogue secretory carcinoma of salivary glands <input type="checkbox"/> Gender identification	<input type="checkbox"/> <i>ALK</i> <input type="checkbox"/> <i>ROS1</i> <input type="checkbox"/> <i>TFE3</i> <input type="checkbox"/> <i>ETV6</i> <input type="checkbox"/> CEP X/Y

**Fusion analysis by RNA based NGS**
 **NTRK**
**Mutation analysis by NGS for hotspot cancer gene panel or by single gene testing**

<input type="checkbox"/> 50 hotspot cancer gene panel (gene list available on request)			
<input type="checkbox"/> Non-small cell lung cancer.....	<input type="checkbox"/> <i>EGFR/BRAF</i>	<input type="checkbox"/> Melanoma.....	<input type="checkbox"/> <i>BRAF/NRAS/KIT</i>
<input type="checkbox"/> Gastrointestinal stromal tumour.....	<input type="checkbox"/> <i>KIT/PDGFR/BRAF</i>	<input type="checkbox"/> Lynch syndrome...	<input type="checkbox"/> <i>BRAF</i>
<input type="checkbox"/> Lymphoplasmacytic lymphoma.....	<input type="checkbox"/> <i>MYD88</i>	<input type="checkbox"/> Glioma.....	<input type="checkbox"/> <i>IDH1/IDH2</i>
<input type="checkbox"/> Histiocytic and dendritic cell neoplasms	<input type="checkbox"/> <i>BRAF</i>	<input type="checkbox"/> Colorectal cancer	<input type="checkbox"/> <i>KRAS/NRAS/BRAF</i>

 **Microsatellite instability (MSI) testing for LS screening or immunotherapy (delete as appropriate)**

**East Genomic Laboratory Hub**  

MLH1 promoter methylation testing in LS

MGMT promoter methylation testing in glioblastoma

Tissue identity testing by STR genotyping (a reference sample, preferably PB, is required to compare identity)

**Equality and diversity statement**

This document complies with the Cambridge University Hospitals NHS Foundation Trust service equality and diversity statement.

**Disclaimer**

It is your responsibility to check against the electronic library that this printed out copy is the most recent issue of this document. For full approval history of documentation please see relevant Q-Pulse record.